Drugs / HPV-16/18 L1/AS04
HPV-16/18 L1/AS04
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00196924 | Jun 2004 → Mar 2006 | human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2013-12-20 | GlaxoSmithKline | Regulatory GSK Cervarix® two-dose schedule receives European marketing authorisation gsk.com ↗ |
| 2009-07-06 | GlaxoSmithKline | Results Landmark study for GSK’s cervical cancer vaccine published in The Lancet gsk.com ↗
These excellent study results confirm the efficacy offered by Cervarix ® against HPV 16 and 18. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2013-12-20 | GlaxoSmithKline | GSK Cervarix® two-dose schedule receives European marketing authorisation gsk.com ↗ |
| 2009-07-06 | GlaxoSmithKline | Landmark study for GSK’s cervical cancer vaccine published in The Lancet gsk.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPV-16/18 L1/AS04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00196924 ↗ |
| Known as | HPV-16/18 AS04-adjuvanted vaccine | “Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.” PMID 20413076 ↗ May 2010 |
| Known as | HPV-16/18 L1 virus-like particle AS04-adjuvanted vaccine | “Girls (mean age 12 years) in 12 countries received the HPV-16/18 L1 virus-like particle AS04-adjuvanted vaccine (N = 1,035) or hepatitis A virus vaccine as control (N = 1,032)...” PMID 20413076 ↗ May 2010 |
| Modality | Vaccine | “HPV-16/18 L1 virus-like particle AS04-adjuvanted vaccine” PMID 20413076 ↗ May 2010 |
| Route | Intramuscular | “administered intramuscularly” NCT00196924 ↗ |